Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15139597 | 0.75 | ALDH1A1 (0.31) | ADRA2C | |
| SCHEMBL22585784 | 0.72 | ADRA2C (0.32) | ADRA2C | |
| SCHEMBL15139599 | 0.72 | — | — | |
| SCHEMBL2454337 | 0.70 | — | — | |
| SCHEMBL24181272 | 0.69 | KDM4E (0.31) | — | |
| SCHEMBL11088564 | 0.66 | PTGS2 (0.40) | MEN1KMT2A | |
| SCHEMBL13804706 | 0.65 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL3110417 | 0.65 | ADRA2C (0.42) | ADRA2CMEN1PABPC1KMT2A | |
| Hydrochloric Acid SCHEMBL5711451 | 0.64 | ADRA2C (0.40) | ADRA2CMEN1PABPC1KMT2A | |
| SCHEMBL9624456 | 0.63 | MEN1 (0.36) | ADRA2CMEN1PABPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299285-B2 | Compounds for imaging and therapy | ISIS INNOVATION LIMITED (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20110098353-A1 | Compounds for Imaging and Therapy | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| WO-2007003944-A2 | COMPOUNDS FOR IMAGING AND THERAPY | ISIS INNOVATION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2004111052-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR) | XENOVA LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004065389-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF MULTIDRUG RESISTANCE | XENOVA LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098353-A1 | Compounds for Imaging and Therapy | MEN1, XPOT, SLC39A3 | ADRA2C 1035/4885MEN1 1/4885PABPC1 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.